US4908433A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Uses of interleukin-2
Assignee: Novartis Vaccines and Diagnostics Inc
•
Filing: 1988-06-10
•
Granted: 1990-03-13
•
Expires: 2008-06-10
Abstract
Abstract Interleukin 2 (IL 2; T-cell growth factor), produced with and without costimulation by Burkitt's lymphoma line Daudi, is highly purified approximately over 37,000-fold to apparent homogeneity from lymphocyte-conditioned medium derived from normal human blood cells by (NH4)2SO4-precipitation, ion exchange chromatography, gel filtration and hydrophobic chromatography, hp IL-2 is free of pyrogens, B cell inducing factor, B cell growth factor, interferon, CSF, and thymocyte differentiating factor. Nature IL 2 produced in the absence of Daudi cells has a molecular weight of about 26,000 daltons as measured by gel filtration and yields Il 2 having two molecular weights of about 16,000 and 17,000 daltons after denaturation as measured by sodium dodecyl sulfate-poylacrylamide gel electrophoresis, IL 2 produced in the presence of Daudi cells shows a molecular weight of approximately 14,500 daltons as measured by both gel filtration and sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Inventors
- 👤 Roland Mertelsmann
- 👤 Karl Welte
- 👤 Salvatore Venuta
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 22:01
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/54; C07K14/55; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
35 words
A method of normalizing a subject's immune response which comprises administering to the subject an amount of a human interleukin-2 effective to increase the proliferation of T cells and thus normalize the subject's immune response.
Claim 2
Independent Claim
35 words
A method of normalizing a subject's immune response which comprises administering to the subject an amount of a human interleukin-2 effective to increase the proliferation of T cells and thus normalize the subject's immune response.
Claim 3
Dependent Claim
11 words
A method of claim 1, wherein the subject has an immunodeficiency.
Claim 4
Dependent Claim
20 words
A method of claim 2, wherein the immunodeficiency is a congenital immunodeficiency syndrome, Hodgkin's disease, Kaposi's Syndrome, or Nezeloff Syndrome.
Claim 5
Dependent Claim
23 words
A method of claim 2, wherein the immunodeficiency is caused by immunosuppression associated with chemotherapy, radiation therapy or bone transplantation therapy of cancer.
Claim 6
Dependent Claim
15 words
A method of claim 2, wherein the immunodeficiency is associated with Acquired Immune Deficiency Syndrome.
Claim 7
Dependent Claim
39 words
A method of claim 1, wherein the interleukin-2 is selected from the group consisting of interleukin-2s characterized by molecular weights of about 14,500±2,000, 16,000±1,000, 17,000±1,000, and 26,000±4,000 daltons as measured by gel filtration and sodium dodecyl sulfatepolyacrylamide gel electrophoresis.
Claim 8
Dependent Claim
31 words
A method of claim 6, wherein the interleukin-2 is further characterized by a specific activity of at least about 9×10 5 U/mg in the murine interleukin-2 dependent cytotoxic T-cell line assay.
Claim 9
Dependent Claim
17 words
A method of claim 2 which further comprises administering to the subject a lymphokine other than interleukin-2.
Claim 10
Dependent Claim
16 words
A method of claim 8, wherein the lymphokine is administered in combination with the human interleukin-2.
Claim 11
Independent Claim
38 words
A method of treating a subject having an interleukin-2 dependent neoplasia which comprises administering to the subject an amount of a human interleukin-2 in combination with cytotoxin effective to inhibit growth of, or cause regression of, the neoplasia.
Claim 12
Independent Claim
38 words
A method of treating a subject having an interleukin-2 dependent neoplasia which comprises administering to the subject an amount of a human interleukin-2 in combination with cytotoxin effective to inhibit growth of, or cause regression of, the neoplasia.
Claim 13
Dependent Claim
13 words
A method of claim 10, wherein the interleukin-2-dependent neoplasia is acute lymphocytic leukemia.
Claim 14
Dependent Claim
15 words
A method of claim 10, wherein the interleukin-2-dependent neoplasia is a neoplasia of mature T-cells.
Claim 15
Dependent Claim
39 words
A method of claim 10, wherein the interleukin-2 is selected from the group consisting of interleukin-2s characterized by molecular weights of about 14,500±2,000, 16,000±1,000, 17,000±1,000, and 26,000±4,000 daltons as measured by gel filtration and sodium dodecyl sulfatepolyacrylamide gel electrophoresis.
Claim 16
Dependent Claim
32 words
A method of claim 13, wherein the interleukin-2 is further characterized by a specific activity of at least about 9× 10 5 U/mg in the murine interleukin-2 dependent cytotoxic T-cell line assay.
Claim 17
Independent Claim
32 words
A method of treating a subject having an overreactive immunity which comprises administering to the subject an amount of a human interleukin-2 effective to decrease the reactivity of the subject's immune system.
Claim 18
Independent Claim
32 words
A method of treating a subject having an overreactive immunity which comprises administering to the subject an amount of a human interleukin-2 effective to decrease the reactivity of the subject's immune system.
Claim 19
Dependent Claim
12 words
A method of claim 15, wherein the subject has an autoimmune disorder.
Claim 20
Dependent Claim
39 words
A method of claim 15, wherein the interleukin-2 is selected from the group consisting of interleukin-2s characterized by molecular weights of about 14,500±2,000, 16,000±1,000, 17,000±1,000, and 26,000±4,000 daltons as measured by gel filtration and sodium dodecyl sulfatepolyacrylamide gel electrophoresis.
Claim 21
Dependent Claim
31 words
A method of claim 17, wherein the interleukin-2 is further characterized by a specific activity of at least about 9×10 5 U/mg in the murine interleukin-2 dependent cytotoxic T-cell line assay.
Claim 22
Independent Claim
35 words
A method of selectively eliminating interleukin-2 receptor-bearing cells from a subject which comprises administering to the subject an amount of a human interleukin-2 in combination with cytotoxin effective to selectively eliminate the interleukin-2 receptor-bearing cells.
Claim 23
Independent Claim
35 words
A method of selectively eliminating interleukin-2 receptor-bearing cells from a subject which comprises administering to the subject an amount of a human interleukin-2 in combination with cytotoxin effective to selectively eliminate the interleukin-2 receptor-bearing cells.
Claim 24
Dependent Claim
39 words
A method of claim 19, wherein the interleukin-2 is selected from the group consisting of interleukin-2s characterized by molecular weights of about 14,500±2,000, 16,000±1,000, 17,000±1,000, and 26,000±4,000 daltons as measured by gel filtration and sodium dodecyl sulfatepolyacrylamide gel electrophoresis.
Claim 25
Dependent Claim
31 words
A method of claim 19, wherein the interleukin-2 is further characterized by a specific activity of at least about 9×10 5 U/mg in the murine interleukin-2 dependent cytotoxic T-cell line assay.
References Cited (Backward Citations)
US4390523A
Cited
JPS55148098A
Cited
US4315852A
Cited
US4448879A
Cited
US4464355A
Cited
US4401756A
Cited
US4508833A
Cited
EP0088195A2
Cited
US4564593A
Cited
US4450103A
Cited
US4789658A
Cited
EP0091539A1
Cited
US4738927A
Cited
EP0092163A2
Cited
US4778879A
Cited
EP0094317A2
Cited
US4490289A
Cited
US4462940A
Cited
EP0111344A2
Cited
EP0118617A2
Cited
US4511502A
Cited
US4511503A
Cited
US4512922A
Cited
EP0118977A1
Cited
EP0119621A1
Cited
EP0121352A1
Cited
US4518584A
Cited
EP0128467A1
Cited
EP0132359A2
Cited
US4464295A
Cited
US4476049A
Cited
EP0142268A1
Cited
US4675383A
Cited
EP0145390A2
Cited
EP0147819A2
Cited
US4569790A
Cited
US4530787A
Cited
US4530787B1
Cited
EP0158198A1
Cited
EP0158487A2
Cited
US4572798A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-03-12 | 1993-09-11 | 1994-03-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-03-12 | 1997-09-11 | 1998-03-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-03-12 | 2001-09-11 | 2002-03-13 | $7700.00 | Window Closed / Lapsed |